Trial · NCT00246012
Results by group97
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 97
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1 | Intetumumab 3 mg/kg [Phase 1 (Part 1)] | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1 | Intetumumab 5 mg/kg [Phase 1 (Part 1)] | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1 | Intetumumab 10 mg/kg [Phase 1 (Part 1)] | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1 | Dacarbazine + Intetumumab 5 mg/kg [Phase 1 (Part 2)] | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1 | Dacarbazine + Intetumumab 10 mg/kg [Phase 1 (Part 2)] | 0 | Participants | ||
| Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 1) | Intetumumab 3 mg/kg [Phase 1 (Part 1)] | 94.44 | Standard Deviation 9.037 | Microgram per milliliter (mcg/mL) | |
| Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 1) | Intetumumab 5 mg/kg [Phase 1 (Part 1)] | 199.45 | Standard Deviation 64.093 | Microgram per milliliter (mcg/mL) | |
| Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 1) | Intetumumab 10 mg/kg [Phase 1 (Part 1)] | 306.86 | Standard Deviation 54.979 | Microgram per milliliter (mcg/mL) | |
| Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 1) | Intetumumab 3 mg/kg [Phase 1 (Part 1)] | 257.55 | Standard Deviation NA | mcg*day/mL | |
| Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 1) | Intetumumab 5 mg/kg [Phase 1 (Part 1)] | 503.71 | Standard Deviation NA | mcg*day/mL | |
| Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 1) | Intetumumab 10 mg/kg [Phase 1 (Part 1)] | 1479.07 | Standard Deviation 149.851 | mcg*day/mL | |
| Half-life of Intetumumab - Phase 1 (Part 1) | Intetumumab 3 mg/kg [Phase 1 (Part 1)] | 2.03 | Standard Deviation NA | Days | |
| Half-life of Intetumumab - Phase 1 (Part 1) | Intetumumab 5 mg/kg [Phase 1 (Part 1)] | 2.13 | Standard Deviation NA | Days | |
| Half-life of Intetumumab - Phase 1 (Part 1) | Intetumumab 10 mg/kg [Phase 1 (Part 1)] | 5.33 | Standard Deviation 1.001 | Days | |
| Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 1) | Intetumumab 3 mg/kg [Phase 1 (Part 1)] | 11.85 | Standard Deviation NA | mL/day/kg | |
| Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 1) | Intetumumab 5 mg/kg [Phase 1 (Part 1)] | 9.96 | Standard Deviation NA | mL/day/kg | |
| Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 1) | Intetumumab 10 mg/kg [Phase 1 (Part 1)] | 6.79 | Standard Deviation 1.634 | mL/day/kg | |
| Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 1) | Intetumumab 3 mg/kg [Phase 1 (Part 1)] | 34.69 | Standard Deviation NA | mL/kg | |
| Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 1) | Intetumumab 5 mg/kg [Phase 1 (Part 1)] | 30.63 | Standard Deviation NA | mL/kg | |
| Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 1) | Intetumumab 10 mg/kg [Phase 1 (Part 1)] | 50.80 | Standard Deviation 4.981 | mL/kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00246012/results